LIVIVO - Search results -

Search results

Result 1 - 9 of total 9

Search options

Article: Prevention in Daily Life against Progression of COVID-19.

Murakami, Mutsumi / Ikeda, Yuka / Tsuji, Ai / Matsuda, Satoru

International journal of preventive medicine

2020 Volume 11, Page(s) 99

Keywords	covid19
Language	English
Publishing date	2020-07-09
Publishing country	Iran
Document type	Journal Article
ZDB-ID	2574680-7
ISSN	2008-8213 ; 2008-7802
ISSN (online)	2008-8213
ISSN	2008-7802
DOI	10.4103/ijpvm.IJPVM_219_20
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Prevention in Daily Life against Progression of COVID-19

Murakami, M. / Ikeda, Y. / Tsuji, A. / Matsuda, S.

Int J Prev Med

Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #845331
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Prevention in daily life against progression of COVID-19

Mutsumi Murakami / Yuka Ikeda / Ai Tsuji / Satoru Matsuda

International Journal of Preventive Medicine, Vol 11, Iss 1, Pp 99-

2020 Volume 99

Keywords	Medicine ; R ; covid19
Language	English
Publishing date	2020-01-01T00:00:00Z
Publisher	Wolters Kluwer Medknow Publications
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Oral antivirals for the prevention and treatment of SARS-CoV-2 infection.

Soriano, Vicente / de-Mendoza, Carmen / Edagwa, Benson / Treviño, Ana / Barreiro, Pablo / Fernandez-Montero, José V / Gendelman, Howard E

AIDS reviews

2022 Volume 24, Issue 1, Page(s) 41–49

Abstract: ... threatening viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against severe COVID-19 ... remains a growing threat. This is highlighted by the current surge of the omicron COVID-19 variant ... will likely transform the landscape of the COVID-19 pandemic. ...

Abstract	Vaccines and antivirals are the classical weapons deployed to contain, prevent, and treat life-threatening viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against severe COVID-19 disease manifestations and complications. However, waning immunity and emergence of vaccine escape mutants remains a growing threat. This is highlighted by the current surge of the omicron COVID-19 variant. Thus, there is a race to find treatment alternatives. We contend that oral small molecule antivirals that halt SARSCoV- 2 infection are essential. Compared to currently available monoclonal antibodies and remdesivir, where parenteral administration is required, oral antivirals offer treatments in an outpatient setting with dissemination available on a larger scale. In response to this need at 2021's end, regulatory agencies provided emergency use authorization for both molnupiravir and nirmatrelvir. These medicines act on the viral polymerase and protease, respectively. Each is given for 5 days and can reduce disease progression by 30% and 89%, respectively. The advent of additional oral antivirals, the assessment of combination therapies, the formulation of extended-release medications, and their benefit for both early treatment and prophylaxis will likely transform the landscape of the COVID-19 pandemic.
MeSH term(s)	Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; HIV Infections/drug therapy ; Humans ; Pandemics/prevention & control ; SARS-CoV-2
Chemical Substances	Antiviral Agents
Language	English
Publishing date	2022-03-01
Publishing country	Spain
Document type	Journal Article
ZDB-ID	2086783-9
ISSN	1698-6997 ; 1139-6121
ISSN (online)	1698-6997
ISSN	1139-6121
DOI	10.24875/AIDSRev.22000001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5711: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Early 3‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study.

Georgakopoulou, Vasiliki Epameinondas / Gkoufa, Aikaterini / Makrodimitri, Sotiria / Basoulis, Dimitrios / Tsakanikas, Aristeidis / Karamanakos, Georgios / Mastrogianni, Elpida / Voutsinas, Pantazis M / Spandidos, Demetrios A / Papageorgiou, Chrysovalantis V / Gamaletsou, Maria N / Sipsas, Nikolaos V

Experimental and therapeutic medicine

2023 Volume 26, Issue 4, Page(s) 462

Abstract: ... 100 mg on days 2 and 3. The efficacy endpoints were set as the need for COVID-19-related ... enrolled completed the 3-day course, with a total of 6 out of 143 patients (4.2%) having a COVID-19-related ... in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving to be effective ...

Abstract	Remdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in hospitalized patients, remdesivir leads to improved outcomes in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving to be effective in hospitalized patients, its use gained approval in early-stage disease for symptomatic outpatients who are at a high risk of progression to severe disease. The present study is a real-life prospective cohort study involving 143 elderly non-hospitalized patients with SARS-CoV-2 (≥65 years of age) who attended the emergency department of the authors' hospital seeking care for COVID-19 symptoms appearing within the prior 7 days. Eligible patients received intravenous remdesivir at a dose of 200 mg on the first day and 100 mg on days 2 and 3. The efficacy endpoints were set as the need for COVID-19-related hospitalization and all-cause mortality in the following 28 days. A total of 143 patients participated in the study. Of these patients, 118 (82.5%) patients were vaccinated with at least two doses. All patients enrolled completed the 3-day course, with a total of 6 out of 143 patients (4.2%) having a COVID-19-related hospitalization by day 28, and 5 patients (3.5%) succumbing to the disease within the study period. In the univariate Cox regression analysis, the neutrophil-to-lymphocyte ratio and haematological malignancy were identified as predictors of progression to severe disease, and albumin levels, the C-reactive protein-to-albumin ratio (CAR) and haematological malignancy were identified as predictors of 28-day mortality. On the whole, the findings of the present study demonstrated that among the elderly outpatients, a 3-day course of intravenous remdesivir was associated with favourable outcomes.
Language	English
Publishing date	2023-08-09
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2683844-8
ISSN	1792-1015 ; 1792-0981
ISSN (online)	1792-1015
ISSN	1792-0981
DOI	10.3892/etm.2023.12161
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: The Measures and Achievement of Community Epidemic Prevention against COVID-19 in Taiwan

Hsu, Chia-Yu / Chen, Hsiao-Tan / Wang, En-Tzu / Liu, Hui-Rong / Yang, Chin-Hui

Epidemiology Bulletin

Abstract: COVID-19 is an emerging infectious disease occurred in Wuhan, China at the end of 2019 The epidemic ... of COVID-19 through rigid community defense lines Relevant measures included strengthening the notification ... to the epidemic status of COVID-19 Most importantly, the CECC will make every efforts to reduce the risks ...

Abstract	COVID-19 is an emerging infectious disease occurred in Wuhan, China at the end of 2019 The epidemic began to spread in early 2020 and had become a global pandemic In order to prevent the disease from entering the community and causing continuous transmission, Taiwan had successfully curbed the spread of COVID-19 through rigid community defense lines Relevant measures included strengthening the notification of suspected cases, launching an expanded community surveillance program, detecting submerged cases effectively, and following by prompt isolation and adequate treatment, monitoring cases progression throughout the whole medical process Furthermore, to implement home isolation and home quarantine policy, the Central Epidemic Command Center (CECC) established appropriate tracking and following up systems on persons at risk of infection with smart technology and inter-ministerial cooperation In addition, the CECC published epidemic prevention guidelines and provided advices for crowded places or activities to strengthen epidemic prevention at those with high risks of infection Moreover, through multiple channels and platforms, the CECC established communication with the public regarding risks of infection and raised the public’s awareness of epidemic prevention among our people Thanks to the collective efforts of the public and strict border controls, the epidemic was under stable situation The CECC substantially lifted the restrictions since June 7, so that the public and industries could return to normalcy Lastly, to be prepared for the future border controls adjustments, personal health behaviors must be cultivated and rooted deeply in our daily lives In addition to closely monitoring the epidemic situations and trends, The CECC continues to encourage our people to implement the ＂Epidemic New Life Movement＂ and timely adjust the epidemic prevention strategies according to the epidemic status of COVID-19 Most importantly, the CECC will make every efforts to reduce the risks of community transmission and protect the health of our people
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #709708
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study.

Scotto, Riccardo / Buonomo, Antonio Riccardo / Iuliano, Antonio / Foggia, Maria / Sardanelli, Alessia / Villari, Riccardo / Pinchera, Biagio / Gentile, Ivan / Federico Ii Covid-Team

Vaccines

2023 Volume 11, Issue 2

Abstract: Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID ... with a diagnosis of SARS-CoV-2 infection who referred to the COVID-19 early treatment service ... 19 in fragile and immunocompromised patients. In this real-life, prospective, observational study ...

Abstract	Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patients with a diagnosis of SARS-CoV-2 infection who referred to the COVID-19 early treatment service of Infectious Diseases Unit of University of Naples Federico from 10 January 2022 to 31 March 2022. The included patients could be treated with either remdesivir alone or with remdesivir plus a monoclonal antibody with activity against SARS-CoV-2. Among the 62 included patients, we showed low rates of hospitalization (8%), increase in oxygen supplementation (3.2%), ICU admission (1.6%) and death (1.6%). The rate of disease progression was 8% and it was similar in patients treated with remdesivir alone or in combination with monoclonal antibodies (6.7% and 9.4%, respectively;
Language	English
Publishing date	2023-01-17
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines11020200
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".

Teofili, Luciana / Landolfi, Raffaele / Cingolani, Antonella / Antinori, Andrea / Vecchiet, Jacopo / Sanguinetti, Maurizio / Gasbarrini, Antonio / Pasciuto, Tina / Orlando, Nicoletta / Lamonica, Silvia

Trials

2020 Volume 21, Issue 1, Page(s) 875

Abstract: ... prevents progression to severe pneumonia in elderly COVID-19 pneumonia patients with chronic comorbidities ... Objectives: The primary objective is to demonstrate that COVID-19 convalescent plasma (CCP ... COVID-19 who are at risk according to CDC definition are eligible. Inclusion criteria are ...

Abstract	Objectives: The primary objective is to demonstrate that COVID-19 convalescent plasma (CCP) prevents progression to severe pneumonia in elderly COVID-19 pneumonia patients with chronic comorbidities. Secondary objectives are to demonstrate that CCP decreases the viral load in nasopharyngeal swabs and increases the anti-SARS-CoV-2 antibody titre in recipients. Trial design: This is a randomized, open-label, parallel group, phase II/III study with a superiority framework. The trial starts with a screening phase II designed with two-tailed alpha=0.2. In case of positive results, the trial will proceed in a formally comparative phase III (alpha=0.05). Participants: Adult patients with confirmed or suspected COVID-19 who are at risk according to CDC definition are eligible. Inclusion criteria are all the following: age ≥ 65; pneumonia at CT scan; PaO2/FiO2 ≥300 mmHg; presence of one or more comorbidities; signed informed consent. Exclusion criteria are one of the following: age < 65; PaO2/FiO2 < 300 mmHg; pending cardiopulmonary arrest; refusal to blood product transfusions; severe IgA deficiency; any life-threatening comorbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion. The trial is being conducted at three reference COVID-19 centres in the middle of Italy. Intervention and comparator: Intervention: COVID-19 Convalescent Plasma (CCP) in addition to standard therapy. Patients receive three doses (200 ml/day on 3 consecutive days) of ABO matched CCP. Comparator: Standard therapy MAIN OUTCOMES: A. Primary outcome for Phase II: Proportion of patients without progression in severity of pulmonary disease, defined as worsening of 2 points in the ordinal scale of WHO by day 14. B. Primary outcome for Phase III: Proportion of patients without progression in severity of pulmonary disease, defined as worsening of 2 points in the ordinal scale of WHO by day 14. Secondary outcomes for Phase III: Decreased viral load on nasopharyngeal swab at days 6, 9 and 14; Decreased viremia at days 6 and 9; Increased antibody titer against SARS-CoV2 at days 30 and 60; Proportion of patients with negative of SARS-CoV2 nasopharyngeal swab at day 30; Length of hospital stay; Mortality rate at day 28; Total plasma related adverse event (day 60); Total non-plasma related adverse events (day 60); Severe adverse events (SAE) (day 60). Randomisation: Treatment allocation is randomized with a ratio 1:1 in both phase II and phase III. Randomization sequences will be generated at Fondazione Policlinico Gemelli IRCCS through the RedCap web application. Randomized stratification is performed according to age (under/over 80 years), and sex. Blinding (masking): None, this is an open-label trial. Numbers to be randomised (sample size): Phase II: 114 patients (57 per arm). Phase III: 182 patients (91 per arm) TRIAL STATUS: The trial recruitment started on May 27, 2020. The anticipated date of recruitment completion is April 30, 2021. The protocol version is 2 (May 10, 2020). Trial registration: The trial has been registered on ClinicalTrials.gov (May 5, 2020). The Identifier number is NCT04374526 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
MeSH term(s)	Aged ; Aged, 80 and over ; Betacoronavirus/genetics ; Betacoronavirus/immunology ; Blood Transfusion/methods ; COVID-19 ; Comorbidity ; Coronavirus Infections/epidemiology ; Coronavirus Infections/therapy ; Coronavirus Infections/virology ; Disease Progression ; Female ; Humans ; Immunization, Passive/adverse effects ; Immunization, Passive/methods ; Informed Consent/ethics ; Italy/epidemiology ; Male ; Mortality/trends ; Pandemics ; Pneumonia/diagnostic imaging ; Pneumonia/prevention & control ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/therapy ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Tomography, X-Ray Computed/methods ; Viral Load/immunology ; Viral Load/statistics & numerical data
Keywords	covid19
Language	English
Publishing date	2020-10-22
Publishing country	England
Document type	Clinical Trial, Phase II ; Clinical Trial, Phase III ; Comparative Study ; Letter ; Randomized Controlled Trial
ZDB-ID	2040523-6
ISSN	1745-6215 ; 1468-6694 ; 1745-6215
ISSN (online)	1745-6215
ISSN	1468-6694 ; 1745-6215
DOI	10.1186/s13063-020-04821-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial"

Trials

Abstract: ... prevents progression to severe pneumonia in elderly COVID-19 pneumonia patients with chronic comorbidities ... OBJECTIVES: The primary objective is to demonstrate that COVID-19 convalescent plasma (CCP ... comparative phase III (alpha=0.05). PARTICIPANTS: Adult patients with confirmed or suspected COVID-19 who are ...

Abstract	OBJECTIVES: The primary objective is to demonstrate that COVID-19 convalescent plasma (CCP) prevents progression to severe pneumonia in elderly COVID-19 pneumonia patients with chronic comorbidities. Secondary objectives are to demonstrate that CCP decreases the viral load in nasopharyngeal swabs and increases the anti-SARS-CoV-2 antibody titre in recipients. TRIAL DESIGN: This is a randomized, open-label, parallel group, phase II/III study with a superiority framework. The trial starts with a screening phase II designed with two-tailed alpha=0.2. In case of positive results, the trial will proceed in a formally comparative phase III (alpha=0.05). PARTICIPANTS: Adult patients with confirmed or suspected COVID-19 who are at risk according to CDC definition are eligible. Inclusion criteria are all the following: age ≥ 65; pneumonia at CT scan; PaO2/FiO2 ≥300 mmHg; presence of one or more comorbidities; signed informed consent. Exclusion criteria are one of the following: age < 65; PaO2/FiO2 < 300 mmHg; pending cardiopulmonary arrest; refusal to blood product transfusions; severe IgA deficiency; any life-threatening comorbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion. The trial is being conducted at three reference COVID-19 centres in the middle of Italy. INTERVENTION AND COMPARATOR: Intervention: COVID-19 Convalescent Plasma (CCP) in addition to standard therapy. Patients receive three doses (200 ml/day on 3 consecutive days) of ABO matched CCP. Comparator: Standard therapy MAIN OUTCOMES: A. Primary outcome for Phase II: Proportion of patients without progression in severity of pulmonary disease, defined as worsening of 2 points in the ordinal scale of WHO by day 14. B. Primary outcome for Phase III: Proportion of patients without progression in severity of pulmonary disease, defined as worsening of 2 points in the ordinal scale of WHO by day 14. Secondary outcomes for Phase III: Decreased viral load on nasopharyngeal swab at days 6, 9 and 14; Decreased viremia at days 6 and 9; Increased antibody titer against SARS-CoV2 at days 30 and 60; Proportion of patients with negative of SARS-CoV2 nasopharyngeal swab at day 30; Length of hospital stay; Mortality rate at day 28; Total plasma related adverse event (day 60); Total non-plasma related adverse events (day 60); Severe adverse events (SAE) (day 60). RANDOMISATION: Treatment allocation is randomized with a ratio 1:1 in both phase II and phase III. Randomization sequences will be generated at Fondazione Policlinico Gemelli IRCCS through the RedCap web application. Randomized stratification is performed according to age (under/over 80 years), and sex. BLINDING (MASKING): None, this is an open-label trial. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Phase II: 114 patients (57 per arm). Phase III: 182 patients (91 per arm) TRIAL STATUS: The trial recruitment started on May 27, 2020. The anticipated date of recruitment completion is April 30, 2021. The protocol version is 2 (May 10, 2020). TRIAL REGISTRATION: The trial has been registered on ClinicalTrials.gov (May 5, 2020). The Identifier number is NCT04374526 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #886002
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

To top

Search results

Search options

Article: Prevention in Daily Life against Progression of COVID-19.

More links

Kategorien

Order via subito

Article: Prevention in Daily Life against Progression of COVID-19

Kategorien

Inter-library loan at ZB MED

Article ; Online: Prevention in daily life against progression of COVID-19

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Article ; Online: Oral antivirals for the prevention and treatment of SARS-CoV-2 infection.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Early 3‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study.

More links

Kategorien

Order via subito

Article: The Measures and Achievement of Community Epidemic Prevention against COVID-19 in Taiwan

Kategorien

Inter-library loan at ZB MED

Article: Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study.

More links

Kategorien

Order via subito

Article ; Online: "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".

More links

Kategorien

Order via subito

Article: "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial"

Kategorien

Inter-library loan at ZB MED